The Europe Artificial Intelligence in Diagnostics Market is expected to witness market growth of 20.8% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Artificial Intelligence in Diagnostics Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $326 million by 2031. The UK market is exhibiting a CAGR of 19.8% during 2024-2031. Additionally, the France market is expected to experience a CAGR of 21.9% during 2024-2031.
Artificial Intelligence is revolutionizing the healthcare industry, particularly diagnostics, by improving efficiency, accuracy, and patient outcomes. AI-driven diagnostic tools are transforming how diseases are detected, analyzed, and treated, reducing the dependency on manual evaluation and enhancing precision. AI is being increasingly adopted in various diagnostic applications, including radiology, pathology, cardiology, oncology, and genomics, where it assists in identifying diseases at early stages, predicting patient risks, and optimizing treatment plans. The growing demand for AI in diagnostics is fuelled by advancements in deep learning, machine learning (ML), and natural language processing (NLP), which enable faster and more accurate decision-making.
Moreover, the increasing prevalence of chronic diseases, a rising aging population, and the need for cost-effective healthcare solutions drive the widespread adoption of AI in diagnostics. AI also addresses challenges such as a shortage of skilled healthcare professionals and high diagnostic errors. The artificial intelligence in diagnostics market is witnessing significant growth, with healthcare institutions and governments investing heavily in AI-based diagnostic solutions.
In Italy, ICT expenditures in healthcare reached $1.98 billion in 2022, marking a 7% increase from 2021. The government’s €1.67 billion investment in electronic medical records (EMR) and e-health infrastructure, along with an additional €1 billion for telemedicine, is accelerating the adoption of AI-driven diagnostics. With only 35% of the population currently using EMR, there is a large potential for AI-powered predictive analytics and automated diagnostics to enhance patient management. AI-integrated EMR and telemedicine solutions will improve remote diagnostics, personalized treatment plans, and real-time health monitoring, addressing Italy’s healthcare modernization goals.
The Germany market dominated the Europe Artificial Intelligence in Diagnostics Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $326 million by 2031. The UK market is exhibiting a CAGR of 19.8% during 2024-2031. Additionally, the France market is expected to experience a CAGR of 21.9% during 2024-2031.
Artificial Intelligence is revolutionizing the healthcare industry, particularly diagnostics, by improving efficiency, accuracy, and patient outcomes. AI-driven diagnostic tools are transforming how diseases are detected, analyzed, and treated, reducing the dependency on manual evaluation and enhancing precision. AI is being increasingly adopted in various diagnostic applications, including radiology, pathology, cardiology, oncology, and genomics, where it assists in identifying diseases at early stages, predicting patient risks, and optimizing treatment plans. The growing demand for AI in diagnostics is fuelled by advancements in deep learning, machine learning (ML), and natural language processing (NLP), which enable faster and more accurate decision-making.
Moreover, the increasing prevalence of chronic diseases, a rising aging population, and the need for cost-effective healthcare solutions drive the widespread adoption of AI in diagnostics. AI also addresses challenges such as a shortage of skilled healthcare professionals and high diagnostic errors. The artificial intelligence in diagnostics market is witnessing significant growth, with healthcare institutions and governments investing heavily in AI-based diagnostic solutions.
In Italy, ICT expenditures in healthcare reached $1.98 billion in 2022, marking a 7% increase from 2021. The government’s €1.67 billion investment in electronic medical records (EMR) and e-health infrastructure, along with an additional €1 billion for telemedicine, is accelerating the adoption of AI-driven diagnostics. With only 35% of the population currently using EMR, there is a large potential for AI-powered predictive analytics and automated diagnostics to enhance patient management. AI-integrated EMR and telemedicine solutions will improve remote diagnostics, personalized treatment plans, and real-time health monitoring, addressing Italy’s healthcare modernization goals.
List of Key Companies Profiled
- Siemens Healthineers AG (Siemens AG)
- Zebra Technologies Corporation
- GE HealthCare Technologies, Inc.
- F.Hoffmann-La Roche Ltd.
- Microsoft Corporation
- NVIDIA Corporation
- IBM Corporation
- DeepScribe Inc.
- AliveCor, Inc.
- Digital Diagnostics, Inc. (3Derm Systems, Inc.)
Market Report Segmentation
By Component
- Software
- Hardware
- Services
By Diagnosis
- Neurology
- Radiology
- Chest & Lung
- Oncology
- Cardiology
- Pathology
- Other Diagnosis
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Artificial Intelligence in Diagnostics Market by Component
Chapter 6. Europe Artificial Intelligence in Diagnostics Market by Diagnosis
Chapter 7. Europe Artificial Intelligence in Diagnostics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Siemens Healthineers AG (Siemens AG)
- Zebra Technologies Corporation
- GE HealthCare Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Microsoft Corporation
- NVIDIA Corporation
- IBM Corporation
- DeepScribe Inc.
- AliveCor, Inc.
- Digital Diagnostics, Inc. (3Derm Systems, Inc.)
Methodology
LOADING...
